Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.45 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | PAK4 | O96013 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | LTK | P29376 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283442 | 0.93 | LRRK2 (0.55) | LRRK2PTK2SYKALKAURKB | |
| SCHEMBL3279212 | 0.82 | BRD4 (0.53) | PTK2SYKALKJAK2JAK3 | |
| SCHEMBL14547762 | 0.80 | CYP1A2 (0.42) | LRRK2PTK2SYKALKAURKB | |
| SCHEMBL3286833 | 0.80 | LRRK2 (0.57) | LRRK2PTK2SYKDAPK3MAP4K4 | |
| SCHEMBL3280599 | 0.80 | PTK2 (0.57) | PTK2JAK2JAK3PDGFRBPDGFRA | |
| SCHEMBL14287378 | 0.78 | LRRK2 (0.69) | LRRK2PTK2SYKALKAURKB | |
| SCHEMBL14547697 | 0.77 | PAK4 (0.51) | PTK2ALKEML4PAK4MAPK8 | |
| SCHEMBL3285562 | 0.76 | SYK (0.41) | PTK2SYKALKEML4KDR | |
| SCHEMBL14287388 | 0.75 | LRRK2 (0.68) | LRRK2PTK2SYKALKAURKB | |
| SCHEMBL5119258 | 0.75 | LRRK2 (0.65) | LRRK2PTK2SYKALKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | claimed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | LRRK2 276/4885PTK2 196/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.